{"ATC Code":"C - Cardiovascular system","Abbreviation":"","Aliases":["nylidrin","Buphenin","Nilidrine","Suprifen-psb","Nylidrinum","Phenyl-sec-butyl norsuprifen","SKF 1700-A","Benzenemethanol, 4-hydroxy-α-(1-((1-methyl-3-phenylpropyl)amino)ethyl)-","CS 6712","p-Hydroxy-N-(1-methyl-3-phenylpropyl)norephedrine"],"Biological Half-Life":"Duration of action is 10h.","CAS":"447-41-6","ChEBI":"CHEBI:91656","ChEMBL":"CHEMBL114655","ChemicalClasses":["phenylethanolamine"],"Chirality":"unknown","Classes":null,"Color/Form":"Crystals from methanol","Dosing Info":[],"Drug Indication":"Nylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor).","Drug Warnings":".../IT/ SHOULD NOT BE USED IN PT WITH ANGINA PECTORIS OR WITH RECENT OR OLD MYOCARDIAL INFARCTIONS.","DrugClasses":[],"EINECS":"207-182-2","EliminationHalfLife":"","European Community (EC) Number":"207-182-2","HMDB ID":"HMDB0255826","HeavyAtomCount":22,"Human Drugs":"Pharmaceuticals","IUPACName":"4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol","InChI":"InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3","InChIKey":"PTGXAUBQBSGPKF-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)","Melting Point":"111 °C","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e25\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"299.4 g/mol","Odor":"ODORLESS","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Nylidrin hydrochloride acts mainly by beta-receptor stimulation,. Beta stimulation with nylidrin has been studied and confirmed in a variety of isolated tissues from rabbits, guinea pigs, as well as dogs. This drug has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat as well as the unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of mechanisms is an improved blood supply to ischemic tissues, with minimal change in blood pressure (generally).     Nylidrin causes peripheral vasodilation, a positive inotropic effect, and an increased volume of gastric acid.,.  According to one study, there are two primary effects of this agent following the intra‐arterial route of administration: one, to decrease total peripheral resistance; and two, a direct effect on the heart tissue to increase cardiac output.  It also acts directly on the arteries and arterioles of the skeletal muscles. Additionally, it suppresses uterine contractility thereby preventing or halting premature labor.","PrevSalts":[],"PubChemId":4567,"Record Description":["4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol is an alkylbenzene.","Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment.  Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and certain types of ulcers). This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. This effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers.  FDA has considered nylidrin as \"lacking substantial evidence of effectiveness\" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. Therefore, the FDA has withdrawn nylidrin from the U.S. market.","NYLIDRIN is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.","A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.","4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol is an alkylbenzene."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Buphenine","Name":"Buphenine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q851507","Name":"Buphenine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB06152","Name":"Buphenine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4567","Name":"Buphenine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL114655","Name":"Buphenine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91656","Name":"Buphenine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=447-41-6","Name":"Buphenine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0255826","Name":"Buphenine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D07551","Name":"Buphenine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/695DKH33EI","Name":"Buphenine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4023387","Name":"Buphenine","Sub":false}]}],"SMILES":"CC(CCC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O","Scheduling":[],"Solubility":"Mol wt 335.88. Crystals. Sparingly sol in water; slightly sol in alcohol. Practically insol in ether, chloroform, benzene /Hydrochloride/","StoreUNII":["695DKH33EI"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="57.468mm" version="1.2" viewBox="0 0 166.547 57.468" width="166.547mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="58.0" stroke="none" width="167.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="99.513" x2="99.513" y1="46.767" y2="31.527"/>
                  
            <line class="bond" id="mol1bnd2" x1="99.513" x2="112.711" y1="31.527" y2="23.907"/>
                  
            <line class="bond" id="mol1bnd3" x1="112.711" x2="125.909" y1="23.907" y2="31.527"/>
                  
            <line class="bond" id="mol1bnd4" x1="125.909" x2="139.108" y1="31.527" y2="23.907"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="139.108" x2="152.311" y1="23.907" y2="31.535"/>
                        
                <line x1="141.546" x2="152.311" y1="22.499" y2="28.719"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="152.311" x2="165.509" y1="31.535" y2="23.915"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="165.509" x2="165.504" y1="23.915" y2="8.667"/>
                        
                <line x1="163.07" x2="163.066" y1="22.508" y2="10.074"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="165.504" x2="152.301" y1="8.667" y2="1.038"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="152.301" x2="139.103" y1="1.038" y2="8.658"/>
                        
                <line x1="152.301" x2="141.542" y1="3.854" y2="10.066"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="139.108" x2="139.103" y1="23.907" y2="8.658"/>
                  
            <line class="bond" id="mol1bnd11" x1="99.513" x2="89.468" y1="31.527" y2="25.727"/>
                  
            <line class="bond" id="mol1bnd12" x1="83.161" x2="73.117" y1="25.727" y2="31.527"/>
                  
            <line class="bond" id="mol1bnd13" x1="73.117" x2="73.117" y1="31.527" y2="46.767"/>
                  
            <line class="bond" id="mol1bnd14" x1="73.117" x2="59.918" y1="31.527" y2="23.907"/>
                  
            <line class="bond" id="mol1bnd15" x1="59.918" x2="46.72" y1="23.907" y2="31.527"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="46.72" x2="33.517" y1="31.527" y2="23.898"/>
                        
                <line x1="44.282" x2="33.517" y1="32.934" y2="26.714"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="33.517" x2="20.319" y1="23.898" y2="31.518"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="20.319" x2="20.324" y1="31.518" y2="46.767"/>
                        
                <line x1="22.758" x2="22.762" y1="32.926" y2="45.359"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="20.324" x2="33.527" y1="46.767" y2="54.395"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="33.527" x2="46.725" y1="54.395" y2="46.775"/>
                        
                <line x1="33.527" x2="44.286" y1="51.579" y2="45.368"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="46.72" x2="46.725" y1="31.527" y2="46.775"/>
                  
            <line class="bond" id="mol1bnd22" x1="20.324" x2="10.404" y1="46.767" y2="52.494"/>
                  
            <line class="bond" id="mol1bnd23" x1="59.918" x2="59.918" y1="23.907" y2="12.588"/>
                  
            <g class="atom" id="mol1atm11">
                        
                <path d="M88.255 26.356h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M88.119 20.895h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm21">
                        
                <path d="M9.385 54.384q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM5.521 54.384q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M4.305 56.836h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62v4.899z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm22">
                        
                <path d="M62.178 8.664q-.0 .756 -.256 1.327q-.256 .566 -.757 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.501 .31 .757 .875q.256 .566 .256 1.328zM58.314 8.664q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M66.484 11.116h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="89.468" x2="94.4905" y1="25.727" y2="28.627000000000002"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="89.468" x2="94.4905" y1="25.727" y2="28.627000000000002"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="83.161" x2="78.13900000000001" y1="25.727" y2="28.627000000000002"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="83.161" x2="78.13900000000001" y1="25.727" y2="28.627000000000002"/>
            <line class="hi" id="mol1bnd22" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="52.494" y2="49.6305"/>
            <line class="hi" id="mol1bnd22" stroke="#FF0D0D" x1="10.404" x2="15.364" y1="52.494" y2="49.6305"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="59.918" x2="59.918" y1="12.588" y2="18.2475"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="59.918" x2="59.918" y1="12.588" y2="18.2475"/>
        </g>
          
    </g>
    
</svg>
","Taste":"TASTELESS","Therapeutic Uses":"Mesh Heading: adrenergic beta-Agonists, sympathomimetics, tocolytic Agents, vasodilator Agents","Title":"Buphenine","UNII":"695DKH33EI","Wikidata":"Q851507","Wikipedia":"Buphenine","XLogP":3.5,"pH":"BETWEEN 4.5 \u0026 6.5 (1% SOLN)"}